STAT‐3 contributes to pulmonary fibrosis through epithelial injury and fibroblast‐myofibroblast differentiation
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Lung fibrosis is the hallmark of the interstitial lung diseases. Alveolar epithelial cell (AEC) injury is akey step that contributes to a profibrotic microenvironment. Fibroblasts and myofibroblasts subsequently accumulate and deposit excessive extracellular matrix. In addition to TGF‐β, the IL‐6 family of cytokines, which signal through STAT‐3, may also contribute to lung fibrosis. In the current manuscript, the extent to which STAT‐3 inhibition decreases lung fibrosis is investigated. Phosphorylated STAT‐3 was elevated in lung biopsies from patients with idiopathic pulmonary fibrosis and bleomycin (BLM)‐induced fibrotic murine lungs. C‐188‐9, a small molecule STAT‐3 inhibitor, decreased pulmonary fibrosis in the intraperitoneal BLM model as assessed by arterial oxygen saturation (control, 84.4 ± 1.3%; C‐188‐9, 94.4 ± 0.8%), histology (Ashcroft score: untreated, 5.4 ± 0.25; C‐188‐9, 3.3 ± 0.14), and attenuated fibrotic markers such as diminished α‐smooth muscle actin, reduced collagen deposition. In addition, C‐188‐9 decreased the expression of epithelial injury markers, including hypoxia‐inducible factor‐1α (HIF‐1α) and plasminogen activator inhibitor‐1 (PAI‐1). In vitro studies show that inhibition of STAT‐3 decreased IL‐6‐ and TGF‐β‐induced expression of multiple genes, including HIF‐1α and PAI‐1, in AECs. Furthermore, C‐188‐9 decreased fibroblast‐to‐myofibroblast differentiation. Finally, TGF‐β stimulation of lung fibroblasts resulted in SMAD2/SMAD3‐dependent phosphorylation of STAT‐3. These findings demonstrate that STAT‐3 contributes to the development of lung fibrosis and suggest that STAT‐3 may be a therapeutic target in pulmonary fibrosis.—Pedroza, M., Le, T. T., Lewis, K., Karmouty‐Quintana, H., To, S., George, A. T., Blackburn, M. R., Tweardy, D. J., Agarwal, S. K. STAT‐3 contributes to pulmonary fibrosis through epithelial injury and fibroblast‐myofibroblast differentiation. FASEB J. 30, 129‐140 (2016). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bleomycin induced pulmonary fibrosis occurs in a two-step process: 1) the immediate phase consists of an influx of macrophages and polymorphonuclear leukocytes, which release reactive oxygen species, then 2) extracellular matrix remodeling and collagen deposition [180,181].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [181]
In the citing paper
“Both TTI-101 and S3I-201 have been tested in several mouse models of fibrosis, including bleomycin-induced lung and skin fibrosis (scleroderma) and genetically-engineered models of scleroderma, as well as a model mouse of interstitial kidney fibrosis induced by unilateral ureteral obstruction, in which inhibition of STAT3 phosphorylation by these compounds blocks the development of organ fibrosis”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Pedroza et al., 2016
In the citing paper
“Importantly, in both bleomycin induced skin and lung fibrosis in mice, knockout or pharmacological inhibition of STAT3 ameliorates fibrosis (83) (81). Furthermore, in both models, STAT3 was shown to be downstream of TGFβ signaling, as inhibition of STAT3 prevented TGFβ-induced myofibroblasts formation (81, 83).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [83]
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201 · cited 1×
“Activation of STAT-3 regulates multiple biologic functions, including cell survival, migration, proliferation, and differentiation (51).”
BackgroundInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,680 · cited 1×
“H&Estained lung sections were used to determine the Ashcroft score using 20 microscope fields per section in a blinded manner (41, 42).”
MethodInterleukin-6 family of cytokines and gp130
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,272
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Current literature suggests that injury to type II AECs leads to the expression of injury markers, including HIF-1a, PAI-1, and HSP-70 (45–47, 58–60), and fibrotic markers, including Col1a1, a-SMA, TWIST, and SNAIL (4, 12, 14, 61).”
BackgroundMoeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007 · cited 1×
“The intraperitoneal model is associated with progressive subpleural pulmonary fibrosis, which resembles human pulmonary fibrosis to a greater extent than the intratracheal (40, 56, 57).”
BackgroundWillis, B. C., Liebler, J. M., Luby-Phelps, K., Nicholson, A. G., Crandall, E. D., du Bois, R. M., & Borok, Z. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62351-6 · Cited by 951
The epidemiology of interstitial lung diseases.
Coultas, D. B., Zumwalt, R. E., Black, W. C., & Sobonya, R. E. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.4.7921471 · Cited by 946
Standardized Quantification of Pulmonary Fibrosis in Histological Samples
Hübner, R.-H., Gitter, W., Eddine El Mokhtari, N., Mathiak, M., Both, M., Bolte, H., Freitag-Wolf, S., & Bewig, B. (2008) · BioTechniques · doi:10.2144/000112729 · Cited by 817
Cited by
Items 101–193 of 193
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
“STAT is a downstream signaling molecule from JAK activation with seven subtypes: phosphorylated STAT-3 is elevated in biopsies of patients with IPF and in mice with bleomycin induced pulmonary fibrosis [178–181].”
The TGFβ Induced MicroRNAome of the Trabecular Meshwork
Doyle, C., Callaghan, B., Roodnat, A. W., Armstrong, L., Lester, K., Simpson, D. A. C., Atkinson, S. D., Sheridan, C., McKenna, D. J., & Willoughby, C. E. (2024) · Cells · doi:10.3390/cells13121060 · Cited by 19
Identification of periplakin as a major regulator of lung injury and repair in mice
Besnard, V., Dagher, R., Madjer, T., Joannes, A., Jaillet, M., Kolb, M. R. J., Bonniaud, P., Murray, L. A., Sleeman, M. A., & Crestani, B. (2018) · JCI Insight · doi:10.1172/jci.insight.90163 · Cited by 19
“Recent data also indicate that STAT3 contributes to the development of lung fibrosis as a regulator of TGF-β transcriptional activity (18).”
BackgroundPPARγ mediates the anti-pulmonary fibrosis effect of icaritin
Hua, Q., Huang, X., Xie, W., Zhao, F., Cheng, H., Luo, Z., Han, J., Wang, Z., Zeng, Q., Lin, M., et al. (2021) · Toxicology Letters · doi:10.1016/j.toxlet.2021.06.014 · Cited by 18
Sun, J., Tang, L., Shan, Y., Yu, M., Sheng, L., Huang, L., Cao, H., Dai, H., Wang, F., Zhao, J., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116343 · Cited by 17
Anthelmintic nitazoxanide protects against experimental pulmonary fibrosis
Chen, X., Dong, Y., Yu, Y., Jiang, M., Bu, W., Li, P., Sun, Z., & Dong, D. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16190 · Cited by 17
“Phosphorylated STAT3 was elevated in lung biopsies from patients with idiopathic pulmonary fibrosis and BLM-induced fibrotic murine lungs, and small-molecule STAT3 inhibitor C-188-9 (TTI-101) inhibited pulmonary fibrosis in BLM model (Pedroza et al., 2016).”
BackgroundQin, Y.-C., Zhao, P., Chen, Y., Liu, X., Dong, H., Zheng, W., Li, C., Mao, X., & Li, J. (2019) · Human & Experimental Toxicology · doi:10.1177/0960327119881678 · Cited by 16
“STAT3 is involved in PF and inflammation.(17,18) In this study, LPS treatment markedly increased the STAT3 DNA-binding of coculture A549 and THP-1 cells (Figure 3).”
BackgroundWang, X., Wang, J., Huang, G., Li, Y., & Guo, S. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11996 · Cited by 16
“Pedroza et al (20) demonstrate that the STAT3 signaling pathway is aberrantly activated in lung biopsies from patients with IPF and in lung tissue from PF animal models.”
Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine
Jones, K. M., Poveda, C., Versteeg, L., Bottazzi, M. E., & Hotez, P. J. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2093721 · Cited by 18
Post-translational modifications of collagen and its related diseases in metabolic pathways
Guo, L., Xiang, W., Pan, Z., He, G., & Jiang, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.02.007 · Cited by 19
Yu, Z., Liu, J., Chen, L., & Xie, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s530754 · Cited by 15
“42,43 Similarly, in peritoneal fibrosis, IL-6/JAK2/STAT3 was shown to be a pro-EMT pathway.”
Advances in common in vitro cellular models of pulmonary fibrosis
Li, D., Zhang, X., Song, Z., Zhao, S., Huang, Y., Qian, W., & Cai, X. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12756 · Cited by 15
“20 examined phosphorylation, the most prevalent form of post-translational protein modification and demonstrated that signal transducer and activator of transcription 3 (STAT-3) phosphorylation plays a role in TGF-b – and IL-6 – induced injury and fibrosis in AECs and lung fibroblasts using MLE-12…”
Zhang, Y., Qi, C., Wei, Q., Li, Y., & Tian, P. (2025) · Respiratory Research · doi:10.1186/s12931-025-03294-7 · Cited by 17
“STAT3 phosphorylation is detected in the fibrotic lung tissue of IPF patients and is involved in fibroblast-to-myofibroblast transition and lung epithelial cell injury; [146], it may be an attractive therapeutic target for IPF.”
Ding, L., Li, Y., Yang, Y., Song, S., Qi, H., Wang, J., Wang, Z., Zhao, J., Zhang, W., Zhao, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.762998 · Cited by 18
“The degrees of inflammatory and fibrotic injuries in the lung tissues were scored according to the Mikawar and Ashcroft methods, respectively (Katoh et al., 1998; Pedroza et al., 2016).”
MethodLi, H., Zhao, C., Muhetaer, G., Guo, L., Yao, K., Zhang, G., Ji, Y., Xing, S., Zhou, J., & Huang, X. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154301 · Cited by 15
Wei, J., Zhan, J., Ji, H., Xu, Y., Xu, Q., Zhu, X., & Liu, Y. (2023) · Antioxidants · doi:10.3390/antiox12081634 · Cited by 16
“In addition, STAT3 also regulates IL-6–mediated and TGF-β1–mediated myofibroblast differentiation in both murine and human lung fibroblasts [62,63].”
BackgroundThe Role of Macrophages in Lung Fibrosis and the Signaling Pathway
Wang, X., Zhou, J., Li, X., Liu, C., Liu, L., & Cui, H. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01253-5 · Cited by 17
CXCL16 Induces the Progression of Pulmonary Fibrosis through Promoting the Phosphorylation of STAT3
Zuo, S., Zhu, Z., Liu, Y., Li, H., Song, S., & Yin, S. (2019) · Canadian Respiratory Journal · doi:10.1155/2019/2697376 · Cited by 16
“It had been confirmed that the signal transducer and activator of transcription 3 (STAT3) is upregulated in lung fibroblasts and alveolar type II cells (ATII), which subsequently leads to lung fibrosis [11, 12].”
BackgroundSu, X., Tan, Z., Wang, G., Liu, Z., Gan, C., Yue, L., Liu, H., Xie, Y., Yao, Y., & Ye, T. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114918 · Cited by 13
Zhu, F., Bai, X., Hong, Q., Cui, S., Wang, X., Xiao, F., Li, J., Zhang, L., Dong, Z., Wang, Y., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801273 · Cited by 13
Folate alleviated skin inflammation and fibrosis resulting from impaired homocysteine metabolism
Huang, J., Lu, W., Zhao, S., Cai, Z., Li, L., Hu, Z., Jiang, Y., Deng, J., Tang, Y., Shi, C., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103501 · Cited by 13
“TGF-β 1 has been reported to trigger the activation of the JAK2/STAT3 pathway in human fibroblasts, leading to the activation of pro-fibrotic genes through nuclear translocation [31].”
Lan, Y., Dong, C., Wu, M., Yuan, R., Yang, K., Yang, Z., Chen, Y., Zhang, J., Qi, B., & Lu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1594757 · Cited by 15
Lee, J. H., Jang, J. H., Lee, S., & Her, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412126 · Cited by 17
“Although JAK/STAT activation—particularly STAT3 phosphorylation in epithelial and fibroblast compartments—is demonstrable in IPF [209], it is not the dominant upstream driver, a role played instead by the TGF-β /SMAD, epithelial senescence, and epithelial stress pathways.”
Targeting ATP12A, a Nongastric Proton Pump α Subunit, for Idiopathic Pulmonary Fibrosis Treatment
Abdelgied, M., Uhl, K. L., Chen, O. G., Schultz, C. R., Tripp, K., Peraino, A. M., Paithankar, S., Chen, B., Kakazu, M. T., Castillo-Bahena, A., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0264oc · Cited by 13
Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials
Roofeh, D., Lescoat, A., & Khanna, D. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1836156 · Cited by 12
Wang, D., Wei, Y., Xu, L., & Zhang, J. (2023) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-023-00305-3 · Cited by 11
“This is in line with previous studies [19, 20].”
ResultDissecting crosstalk induced by cell-cell communication using single-cell transcriptomic data
Hou, J., Zhao, W., & Nie, Q. H. (2025) · Nature Communications · doi:10.1038/s41467-025-61149-7 · Cited by 18
Zhang, X., Su, J., Lin, J., Liu, L., Wu, J., Yuan, W., Zhang, Y., Chen, Q., Su, Z. J., Xu, G., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116633 · Cited by 11
Pacurari, M., May, I. D., & Tchounwou, P. B. (2016) · Environmental Toxicology · doi:10.1002/tox.22248 · Cited by 13
“In the present study, we show translocation of NF-jB in response to LPS and MWCNT. Activation of NF-jB and STAT3 are known to induce activation of genes associated with cell proliferation, transformation, and cell migration (Rahman and Fazal, 2011; Pedroza et al., 2015).”
BackgroundThe STATus of STAT3 in Lung Cell Senescence?
Adnot, S., Lipskaia, L., & Bernard, D. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0013ed · Cited by 11
“Moreover, STAT3 has been shown to contribute to pulmonary fibrosis through epithelial injury and fibroblast–myofibroblast differentiation, as well as to epithelial cell differentiation (13, 14).”
InfluentialYamamoto, K., Ioroi, T., Shinomiya, K., Yoshida, A., Harada, K., Fujisawa, M., Omura, T., Ikemi, Y., Nakagawa, S., Yonezawa, A., et al. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504022x16418911579334 · Cited by 10
Abbas, N. A. T., Nafea, O. E., Mohammed, H. O., Samy, W. M., Abdelmageed, A. F., Afifi, R., & Hassan, H. A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121692 · Cited by 13
Li, Y., Zhao, J., Yin, Y., Zhang, C., Zhang, Z., & Zheng, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512210 · Cited by 10
Anoctamin-1 is induced by TGF-β and contributes to lung myofibroblast differentiation
Reed, E. B., Orbeta, S., Miao, B. A., Sitikov, A. S., Chen, B., Levitan, I., Solway, J., Mutlu, G. M., Fang, Y. H., Mongin, A. A., et al. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00155.2023 · Cited by 12
Cell selective BCL-2 inhibition enabled by lipid nanoparticles alleviates lung fibrosis
Diwan, R., Bhatt, H. N., Dong, R., Estevao, I. L., Varela-Ramírez, A., & Nurunnabi, M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.055 · Cited by 11
Su, J., Lartey, D. A., Zanella, G., Hawinkels, L. J. A. C., Matteoli, G., Löwenberg, M., & Barnhoorn, M. C. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf087 · Cited by 15
“72 In a mouse model for autoimmune pulmonary fibrosis, treatment with the JAK1 inhibitor ruxolitinib prevented the upregulation of proinflammatory markers in M1 macrophages and profibrotic markers in M2 macrophages, leading to improvement in lung inflammation and fibrotic lesions.”
Hu, X., Tan, J., Wang, Y., Luan, R., Ding, D., Yue, M., Zhao, M. L., Xue, Q., & Yang, J. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112019 · Cited by 11
Zhu, Y., Duan, X. Y., Cheng, Y. Q., Yao, X., Xu, H., Zhang, K. S., Li, F. S., Yang, F., Liu, L. H., & Yuan, X. J. (2021) · International Journal of Occupational Medicine and Environmental Health · doi:10.13075/ijomeh.1896.01644 · Cited by 10
Therapeutic molecular targets of SSc-ILD
Zhang, Y., & Distler, J. H. W. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319899013 · Cited by 13
Bozzinì, S., Pandolfi, L., Rossi, E. G., Inghilleri, S., Zorzetto, M., Ferrario, G., Carlo, S. D., Politano, G. M. M., SILVESTRI, A. D., Frangipane, V., et al. (2021) · Cells · doi:10.3390/cells10030688 · Cited by 9
“In addition, STAT3 activation is detected in lung biopsies from patients with idiopathic pulmonary fibrosis and bleomycin (BLM)-induced murine fibrotic lungs [35,36].”
Zhang, X., Duan, X., Li, L., & Chen, Y. F. (2022) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12535 · Cited by 10
“It has been reported that alveolar epithelial cell injury is the crucial step in myofibroblast accumulation and profibrotic microenvironment formation in the pulmonary fibrogenesis process.(28) Delbrel et al.”
BackgroundWu, R.-D., Zhang, X., Zhang, X., Sun, L., Xia, T., & Zhang, L. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1287133 · Cited by 12
Ma, J., Ding, L., Zang, X., Wei, R., Yang, Y., Zhang, W., Su, H., Li, X., Li, M., Sun, J., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1437231 · Cited by 9
Interstitial lung disease in rheumatic diseases: an update of the 2018 review
Atzeni, F., Alciati, A., Gozza, F., Masala, I. F., Siragusano, C., & Pipitone, N. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2407536 · Cited by 9
“Moreover, in murine lung fibroblasts, signal transducers and activators of transcription (STAT)3 contributed to lung fibrosis by stimulating interleukin (IL)-6 and TGF-β1-mediated myofibroblast differentiation [29].”
Li, J., Mao, N., Wang, Y., Deng, S., & Chen, K. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.011 · Cited by 12
“176 Similarly, JSI-124, which inhibits the dual activity of p -JAK2/p-STAT3, diminishes FMT in lung fi broblasts and epithelial-mesenchyme transition in ATII cells, and the same inhibitor reduced various fi brosis markers in BLM-induced fi brosis in rats.”
Zhang, D., Dong, Y.-Z., Lv, J., Zhang, B., Zhang, X., & Lin, Z. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03210-8 · Cited by 9
STAT-3 signaling role in an experimental model of nephropathy induced by doxorubicin
Santos, T. C. D. O., Pereira, G., Coutinho, A. G. G., Silva, H. P. D. S., Lima, M. M. S., Dias, F. A. L., de Almeida, D. C., Silva, D. T. D. R. E., Perez, R. F., & Pereira, R. L. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04574-2 · Cited by 9
Skin and lung fibrosis induced by bleomycin in mice: a systematic review
Gülle, S., Çelik, A., Bırlık, M., & Yılmaz, O. (2024) · Reumatismo · doi:10.4081/reumatismo.2024.1642 · Cited by 10
Saliva-derived extracellular vesicles: a promising therapeutic approach for salivary gland fibrosis
Peng, B., Guo, X., Kang, J., Pan, S., Wei, L., Wang, L., Li, B., Han, G., & Cheng, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06620-1 · Cited by 11
“Emerging evidence highlights its pivotal role in fibrotic progression, where STAT3 activation drives myofibroblast expansion, phenotypic activation, and excessive ECM deposition [41, 42].”
Cucinotta, L., Mannino, D., Casili, G., Repici, A., Crupi, L., Paterniti, I., Esposito, E., & Campolo, M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02519-x · Cited by 8
“Several lines of evidence point to the fundamental role of STAT3 in fibroblast plasticity during fibrosis and the pharmacological inhibition of JAK2/STAT3 by KYP-2047 decreased fibrosis in these models [60, 61, 63].”
BackgroundSTATs, promising targets for the treatment of autoimmune and inflammatory diseases
He, X., Liu, P., Luo, Y., Fu, X.-Y., & Yang, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116783 · Cited by 5
Tweardy, D. J. (2022) · PubMed Central · Cited by 6
Self-citationAbdel‐Aziz, A. M., Abdelmonaem, A. A., Thabit, D. M., Marey, H., & Ahmed, S. M. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.117086 · Cited by 6
STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer
Robinson, P., Italia, Z., Italia, Z., Hoang, T., Rodriguez, E., Eckols, T. K., Kasembeli, M. M., Hamana, L., Soto, L. M. S., Mahalingam, R., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110808 · Cited by 5
Self-citationLiu, J., Jin, Y., Wang, B., Zhang, J., & Zuo, S. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13212 · Cited by 5
COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib
Ucciferri, C., Auricchio, A., Marinari, S., Vecchiet, J., & Falasca, K. (2021) · European Journal of Inflammation · doi:10.1177/20587392211036813 · Cited by 4
“In our case the fast improvement of the lungs function and the reduction of lungs fibrosis is explainable with several investigative studies that have shown the importance of STAT3 as an important cellular mediator of TGF-β-induced differentiation of resting fibroblasts into myofibroblasts which in turn increases type…”
ResultSoundararajan, A., Wang, T., & Pattabiraman, P. P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.16.580757 · Cited by 4
Methylated circPTK2 as a driver of fibroblast activation in pulmonary fibrosis
Zhu, Y., Zhao, L., Qin, J., Guo, B., Luo, X., Feng, Z., Wei, J., Huang, X., Chen, X., Lin, Y., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.013 · Cited by 6
Şahin, M., Aydın, H., Altun, A., Derin, M. E., & Şahin, A. (2020) · Archives of Rheumatology · doi:10.46497/archrheumatol.2020.7568 · Cited by 4
Park, E., Park, S.-H., Lee, S. J., Jeong, D., Jin, H. K., Moon, H., Cha, B., Kim, D., Ma, S., Seo, W., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01712 · Cited by 4
Chu, H., Liu, S., Zhang, S., Wang, S., Hong-sheng, C., & Li, L. (2024) · Chinese Journal of Analytical Chemistry · doi:10.1016/j.cjac.2024.100397 · Cited by 3
Mishra, V., Baranwal, V., Mugale, M. N., Sharma, S., & Mishra, R. K. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c01473 · Cited by 4
Nishimura, H., Kawano, H., Sato, S., Imakura, T., Yamashita, Y., Murakami, K., Haji, K., Bando, H., Naito, N., Kagawa, K., et al. (2025) · The Journal of Medical Investigation · doi:10.2152/jmi.72.298 · Cited by 2
Liu, C., & Yuan, X. (2026) · Virology · doi:10.1016/j.virol.2026.110913 · Cited by 2
Mechanisms Underlying the Fibrogenic Responses of Carbon Nanotubes
Manke, A., Rojanasakul, L. W., & Rojanasakul, Y. (2018) · Advances in molecular toxicology · doi:10.1016/b978-0-444-64199-1.00003-8 · Cited by 2
Molecular pathogenesis of fibrosis in systemic sclerosis
Jinnin, M. (2022) · Trends in Immunotherapy · doi:10.24294/ti.v6.i1.1453 · Cited by 2
“In terms of JAK-STAT pathway, inhibition of STAT3 in vitro suppresses the TGF-β-induced differentiation of lung fibroblasts into myofibroblasts and the TGF-β-induced fibrosis-related gene expression[17].”
BackgroundZhou, Y., Li, J., Wang, D., Peng, L., & Chen, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110760 · Cited by 2
STAT3/NAV2 signaling promotes the progression of pulmonary fibrosis
Hu, D., Zhang, X., Wang, D., & Xie, W. (2025) · Molecular & Cellular Toxicology · doi:10.1007/s13273-025-00537-y · Cited by 1
Acetylshikonin alleviates pulmonary fibrosis through inhibition of the STAT3 signaling pathway
Qiu, M., Cheng, J., Sun, A., Zhou, Y., Ma, C., Ye, Y., Zhou, X. Y., Xu, Y., Hong, X., Zhao, C., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115811 · Cited by 1
Khan, F., Verma, P., Singh, A. K., Kumar, M., Gupta, J., Patel, G. K., Singh, S., Kumar, V., Yadav, A. K., & Verma, V. (2026) · Medicina · doi:10.3390/medicina62050859 · Cited by 1
“In another study by Pedroza et al., 2015 [35], during in vitro experiments using A549, a human AEC line, and MLE-12 (murine lung epithelial-12), an immortalized murine AEC line demonstrated that activation of STAT-3 by TGF-β –plays a key role in promoting the expression of genes associated with…”
Zhang, S., Liu, J., Feng, X., Feng, R., Zhang, J. Z., Liu, S., & Lu, Y. (2026) · BMC Cancer · doi:10.1186/s12885-026-15993-5 · Cited by 1
“In addition, prior studies have suggested that osimer-tinib-related signaling may intersect with Wnt-associated pathways in lung cells, providing further biological plausibility for the prominence of CTNNB1 in the present network [30, 32].”
Xiao, T., Bao, J., Liu, X., Huang, H. F., & Zhou, H. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.45 · Cited by 1
Analysis of the Potential Relationship between Aging and Pulmonary Fibrosis Based on Transcriptome
Fu, S., Tang, X., Xu, Y., Song, X., Qian, X., Hu, Y., & Zhang, M. (2022) · Life · doi:10.3390/life12121961 · Cited by 2
McKenna, N. J., Ochsner, S. A., Waich, A., Cala-García, J., Echartrea, M. E. R., Grimm, S. L., Poli, F., Castillo, R. C., Zuluaga, J. D., Poli, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.16.659944 · Cited by 3
Self-citationResearch Progress of High-Mobility Group Box Protein B1 in Respiratory Diseases
邵, 润. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111731
Baricitinib improves the efficacy of nintedanib for the treatment of idiopathic pulmonary fibrosisPreprint
Wan, Q., Li, D., Shang, S., Wu, H., Chen, F., & Li, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-3339636/v1
He, S., Chen, X., Cheng, Q., Zhu, L., Zhang, P., Tong, S., Xue, J., & Du, Y. (2024) · PubMed Central · doi:10.19723/j.issn.1671-167x.2024.03.018
Hua, H.-S., Huang, Y., Lee, H.-S., Liu, C., Chao, W., Chen, B.-C., & Lin, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178178
Thymidine Phosphorylase Drives SARS-CoV-2 Spike Protein-Induced Lung TumorigenesisPreprint
Wallace, C., Gileles‐Hillel, A., Cox, A., Gozal, D., Li, W., & Yue, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.14.694192
Additional file 1 of Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Li, J.-M., Chang, W.-H., Li, L., Yang, D. C. H., Hsu, S.-W., Kenyon, N. J., & Chen, C.-H. (2024) · Figshare · doi:10.6084/m9.figshare.26589909
Liu, T.-T., Sun, H.-F., Tang, M.-Z., Shen, H.-R., Shen, Z., Han, Y.-X., Zhan, Y., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.26754076
Liu, T.-T., Sun, H.-F., Tang, M.-Z., Shen, H.-R., Shen, Z., Han, Y.-X., Zhan, Y., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.26754073
Inhaling hydrogen sulfide continuously induces lung injury via IL-6/IL-10 and occludin
Jia, L., Zhang, H., Ma, Y., Su, R., & Li, Y. (2026) · Toxin Reviews · doi:10.1080/15569543.2026.2612777
“…factor il-10 by qRt-PcR. il-6 is one of the most potent pro-inflammatory and fibrogenic cytokines and can be produced by fibroblasts among others (Pedroza et al. 2016). it plays a key role in immune regulation, inflammation, and regeneration; excessive il-6 can contribute to organismal damage…”
Scaffold compound T4015 attenuates pulmonary fibrosis via suppressing JAK/STAT and NF-κB signaling
Zhang, M., Xu, H., Liu, S., Xu, X., Yin, J., Zhang, X., Zhang, X., Yang, X., Liu, X., Yin, B., et al. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026035
Thymidine phosphorylase promotes SARS-CoV-2 spike protein-driven lung tumor development
Wallace, C., Gileles‐Hillel, A., Cox, A., Gozal, D., Li, W., & Yue, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1798566 · Cited by 2
Sgp130Fc regulates IL-6/JAK2/STAT3 trans-signaling pathway in rat vocal fold fibroblast activation
Gao, M., Li, X., Wang, H., Lin, Y., Hu, R., & Xu, W. (2026) · Experimental Cell Research · doi:10.1016/j.yexcr.2026.115019 · Cited by 1
JAK/STAT signaling in liver disease: a therapeutic target or a context-dependent double-edged sword?
Wang, T., Li, L., & Lu, J. J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08135-9 · Cited by 3
Krueppel-like factors transcriptionally regulate idiopathic pulmonary fibrosis
Bhattacharyya, A., & Syamal, A. K. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101488 · Cited by 1
Cadherin-11 regulation of type II alveolar epithelial cells during pulmonary fibrosis
Pedroza, M., To, S., Smith, J., Mills, T., Chavula, T., Karmouty‐Quintana, H., & Agarwal, S. K. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00164.2026
Self-citationBindingDB (2026) · UC San Diego · doi:10.7270/q2p2742q
Gülle, S., Barış, M., Lebe, B., Ulukuş, Ç., Harmancı, D., Çelik, A., Bırlık, M., & Yılmaz, O. (2026) · Biomedicines · doi:10.3390/biomedicines14112468
Hitchen, N., Handel, E. E., Leslie, C., Ciaccio, P. R. D., Joshua, A., Ardolino, L., Grimison, P., Honeyball, F., Tran, B., McCarthy, L. C., et al. (2026) · Molecular Genetics and Genomics · doi:10.1007/s00438-026-02534-9
“Phosphorylated STAT3 is elevated in BIP, while experimental STAT3 inhibition mitigates bleo - mycin-induced lung injury (Pedroza et al. 2016 ), implicating dysregulated STAT3 signaling in BIP pathogenesis.”
Metadata
- Authors
- Pedroza, M., Le, T. T., Lewis, K., Karmouty‐Quintana, H., To, S., George, A. T., Blackburn, M. R., Tweardy, D. J., & Agarwal, S. K.
- Affiliations
- Baylor College of Medicine (US)
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Agarwal, Sandeep K.
- ORCID
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2015-08-31
- Volume
- 30
- Issue
- 1
- Pages
- 129-140
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC4684532
- OpenAlex
- W1853941740
- Cited by
- 193
- References
- 68
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 24 · 2023: 25 · 2022: 27 · 2021: 20 · 2020: 15 · 2019: 14 · 2018: 17 · 2017: 10 · 2016: 7 · 2015: 1
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The FASEB Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health (R01AR062056, K08AR054404, 2T32AI053831‐11A1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- STAT3, pulmonary fibrosis, idiopathic pulmonary fibrosis, alveolar epithelial cell injury, myofibroblast differentiation, bleomycin-induced lung fibrosis, IL-6 signaling, TGF-beta signaling, HIF-1α, plasminogen activator inhibitor-1, extracellular matrix deposition, therapeutic target
- MeSH terms
- Animals, Bleomycin, Cell Differentiation, Disease Models, Animal, Epithelial Cells, Lung, Male, Mice, Inbred C57BL, STAT3 Transcription Factor, Idiopathic Pulmonary Fibrosis, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.